Ubs Asset Management Americas Inc Chemo Centryx, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

Shares

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $17,026 - $39,782	768 Added 1.1%	70,721 $3.65 Million
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $14,914 - $26,712	971 Added 1.41%	69,953 $1.73 Million
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $212,778 - $374,613	-9,576 Reduced 12.19%	68,982 $1.73 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $160,383 - $353,403	8,726 Added 12.5%	78,558 $2.86 Million
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $306,210 - $460,710	-23,233 Reduced 24.96%	69,832 $1.19 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $323,422 - $1.72 Million	33,725 Added 56.83%	93,065 $1.25 Million
Q1 2021 May 14, 2021	BUY	$49.53 - $68.4 $54,185 - $74,829	1,094 Added 1.88%	59,340 $3.04 Million
Q4 2020 Mar 01, 2021	BUY	$47.25 - $65.16 $483,084 - $666,195	10,224 Added 21.29%	58,246 $3.61 Million
Q3 2020 Nov 13, 2020	SELL	$46.35 - $61.69 $12,653 - $16,841	-273 Reduced 0.57%	48,022 $2.63 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $353,354 - $595,976	9,159 Added 23.4%	48,295 $2.78 Million
Q1 2020 May 15, 2020	SELL	$32.73 - $50.78 $259,778 - $403,040	-7,937 Reduced 16.86%	39,136 $1.57 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $76,850 - $446,321	11,285 Added 31.53%	47,073 $1.86 Million
Q3 2019 Nov 14, 2019	BUY	$6.47 - $8.96 $91,518 - $126,739	14,145 Added 65.36%	35,788 $242,000
Q2 2019 Aug 15, 2019	BUY	$8.31 - $14.85 $179,853 - $321,398	21,643 New	21,643 $0
Q4 2018 Feb 13, 2019	SELL	$9.15 - $12.26 $152,805 - $204,742	-16,700 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$10.62 - $13.98 $177,354 - $233,466	16,700 New	16,700 $0

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.